Dutasteride reduces alcohol’s sedative effects in men in a human laboratory setting and reduces drinking in the natural environment
- 208 Downloads
Preclinical studies support the hypothesis that endogenous neuroactive steroids mediate some effects of alcohol.
The aim of this study was to examine the effect of dutasteride inhibition of 5α-reduced neuroactive steroid production on subjective responses to alcohol in adult men.
Using a within-subject factorial design, 70 men completed four randomly ordered monthly sessions in which pretreatment with 4 mg dutasteride or placebo was paired with a moderate dose of alcohol (0.8 g/kg) or placebo beverage. The pharmacologic effect of dutasteride was measured by an assay of serum androstanediol glucuronide. Self-reports of alcohol effects were obtained at 40-min intervals following alcohol administration using the Biphasic Alcohol Effects Scale (BAES) and the Alcohol Sensation Scale (SS). We used linear mixed models to examine the effects of dutasteride and alcohol on BAES and SS responses and the interaction of dutasteride with the GABRA2 alcohol dependence-associated polymorphism rs279858. We also examined whether exposure to dutasteride influenced drinking in the weeks following each laboratory session.
A single 4-mg dose of dutasteride produced a 70 % reduction in androstanediol glucuronide. Dutasteride pretreatment reduced alcohol effects on the BAES sedation and SS anesthesia scales. There was no interaction of dutasteride with rs279858. Heavy drinkers had fewer heavy drinking days during the 2 weeks following the dutasteride sessions and fewer total drinks in the first week after dutasteride.
These results provide evidence that neuroactive steroids mediate some of the sedative effects of alcohol in adult men and that dutasteride may reduce drinking, presumably through its effects on neuroactive steroid concentrations.
KeywordsNeuroactive steroids Human subjects 5α-Reductase
Supported by NIH grants R01 AA015606 (to JC), K24 AA13736 (to HRK), P60 AA03510 (Alcohol Research Center), and M01 RR06192 (University of Connecticut General Clinical Research Center). The authors thank Linda Burian and Pamela Fall for their expert technical assistance in the conduct of this study.
Conflict of interest
JC, RF, AJA, and TP have no disclosures to make. HK has been a consultant or advisory board member for the following pharmaceutical companies: Alkermes, Lilly, Lundbeck, Pfizer, and Roche. He is also a member of the American Society of Clinical Psychopharmacology’s Alcohol Clinical Trials Initiative, which is supported by Lilly, Lundbeck, AbbVie, and Pfizer. CO has received study supplies from Pfizer Pharmaceuticals for a smoking cessation study.
- Covault J, Gelernter J, Hesselbrock V, Nellissery M, Kranzler HR (2004) Allelic and haplotypic association of GABRA2 with alcohol dependence. Am J Med Genet B Neuropsychiatr Genet 129(1):104–109Google Scholar
- First M, Spitzer R, Gibbon M, Williams J (1995) Structured clinical interview for DSM-IV Axis I disorders—patient edition (SCID - I/P, version 2.0). Biometrics Research Department, New York State Psychiatric Institute, New YorkGoogle Scholar
- Nyberg S, Andersson A, Zingmark E, Wahlstrom G, Backstrom T, Sundstrom-Poromaa I (2005) The effect of a low dose of alcohol on allopregnanolone serum concentrations across the menstrual cycle in women with severe premenstrual syndrome and controls. Psychoneuroendocrinology 30(9):892–901PubMedCrossRefGoogle Scholar
- Porcu P, O'Buckley TK, Alward SE, Song SC, Grant KA, de Wit H, Leslie Morrow A (2010) Differential effects of ethanol on serum GABAergic 3alpha,5alpha/3alpha,5beta neuroactive steroids in mice, rats, cynomolgus monkeys, and humans. Alcohol Clin Exp Res 34(3):432–442PubMedCentralPubMedCrossRefGoogle Scholar
- Sobell LC, Sobell MB (1992) In: Litten R, Allen J (eds) Timeline follow-back: a technique for assessing self-reported alcohol consumption. Measuring alcohol consumption: psychosocial and biochemical methods. Humana Press, Totowa, pp 41–42Google Scholar